What it sells
Evolutionary intelligence for autoimmune disease
Business model breakdown
Workflow: what inputs become what output?
Discovers new autoimmune-disease drugs by harnessing parasite biology and AI-based protein structure prediction.
Economics: what it saves and how it charges
UnverifiedPreclinical drug discovery company; no commercial product or revenue model on site.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.